Business

Moderna to Pay $950 Million to Settle Patent Cases From Arbutus, Genevant

Published

on

Moderna MRNA 15.99%increase; green up pointing triangle will pay $950 million to settle patent litigation by Arbutus Biopharma and Genevant Sciences GmbH.

The vaccine maker said Tuesday that, as part of the settlement agreement, it will appeal to a federal circuit court to argue that it has limited liability due to its status as a government contractor. If the company loses that appeal, it said, it agreed to make an additional payment of up to $1.3 billion within 90 days.

Copyright ©2026 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version